Clinical Trials
11 trialsNCT05413915 2026-05-29
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Terminated
NCT01135329 2026-05-27
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01962636 2026-05-20
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT03246906 2026-05-14
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02629692 2026-05-13
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
Phase 1/2 Terminated
NCT01366612 2026-04-03
FLUBUTBI
Hackensack Meridian Health
Phase 3 Terminated
NCT02381548 2026-01-30
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01570868 2025-12-08
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03320642 2025-10-21
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Phase 1 Terminated
NCT00015847 2025-08-22
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03333486 2025-07-04
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Phase 2 Terminated